



SYN-TECH CHEM.&PHARM.CO.,LTD

Industry Forum

Chen-Ming, Hsiao
Chairman

16 Nov. 2023

 生泰合成工業公司
SYN-TECH CHEM & PHARM CO., LTD

Stock Code : 1777



Safe Harbor Notice

In these presentations and discussions, there are certain forward looking statements regarding the results of operation, financial condition and current expectation about future events. As forward-looking statements relate to events and depend on circumstances in the future, they involve risk and uncertainty.

We do not undertake any obligation to publicly revise or update any forward looking statements for availability of new information, future events or otherwise. Real result probably differ substantially from those expected in these forward-looking statements.

Agenda

01

Company Brief Introduction

- Brief overall
- Main Products
- DMF Registration Status
- Official Audit Records

02

Business and Financial Statements

- Performance for operation

03

Strategy in the Future Development & forward-looking

- Future strategies and forward-looking

 生泰合成工業公司
SYN-TECH CHEM & PHARM CO., LTD

The background features a central photograph of several pieces of laboratory glassware, including Erlenmeyer flasks and beakers, some containing a reddish liquid. This image is overlaid with a large, stylized 'X' shape formed by dark maroon and light beige geometric triangles. The text 'Company Brief Introduction' is centered over the 'X' in a bold, white, sans-serif font with a black drop shadow.

Company Brief Introduction

Brief Overall

● 1982, Nov. 9 established

- ❑ NT\$ 445,917,130
- ❑ C. M. Hsiao, Chairman
- ❑ 218 employees
- ❑ APIs
Animal Drugs
Excipient



● ISO

- ❑ ISO9001
- ❑ ISO14001
- ❑ ISO45001
- ❑ PIC/S GMP
- ❑ GDP



● Awards Record

- ❑ National Award in Medicine Quality
- ❑ National Award of Outstanding Research and Development Award in Pharmaceutical Technology
- ❑ National Innovation Award
- ❑ Industrial Sustainable Excellence Award
- ❑ Small and medium enterprise Innovation Award
- ❑ National Innovation Award renewal

● All-round development

- ❑ Manpower cultivation
- ❑ Business fields
- ❑ Infrastructure
- ❑ Cooperate with academic units
- ❑ Develop new drugs with other enterprises

Category of Main Products



Muscle Relaxants



Topical Anesthetic Agents



Excipient and Animal Drugs



Central Nervous System Drugs




Digestive System Drugs



Cardiovascular Agents



Respiratory System Drugs



**Non- Steroidal Anti- Inflammatory
Antipyretics and Analgesics**



Chemotherapeutic Drugs



Others

DMF/MF Registration Status in Various Countries

COUNTRY	DMF/MF (APIs)
U.S.A	19
Japan	20
Canada	2
Korea	6
European Union	7
China	2
Others	9

40 products have passed the TFDA PIC/S GMP inspection.

Official Audit Records

Name of the Regulatory Authority	1 st Audit year	Number / Audit
U.S.A FDA	1995	7
Taiwan FDA	2002	20
Korea FDA	2007	2
Hungary FDA	2008	1
Australia TGA	2009	2
Japan PMDA	2014	5
Mexico FDA	2015	1
EDQM	2016	1

Customer Audit Records


Audit year	Number / Audit
2019	25
2020	5
2021	7
2022	11
2023	33

The background features a warm-toned photograph of laboratory glassware, including several Erlenmeyer flasks and beakers containing a reddish-brown liquid. This image is overlaid with large, dark maroon and light beige geometric shapes that create a dynamic, angular pattern. The text is centered over the maroon area.

Business and Financial Statements


Revenue of Recent 5 Years

Unit: NT in million




Product Category Revenue Proportion Between 2023 and 2022

Unit: NT in ten thousand



Sale proportion basis on the Area



■ Asia (Except Taiwan and Japan) ■ Japan ■ America ■ Europe ■ Others ■ Taiwan

Data collected form Jan.-Sept., 2023

Revenue Compared Between 2023 and 2022

Unit: NT in million

Item	Jan.-Sept., 2023	Jan.-Sept., 2022	Differences (%)
Operating revenue	843	738	14
Gross profit	314	269	17
Gross profit ratio (%)	37	36	3
Operating profit	220	177	24
Profit before tax	282	326	(13)
Profit after tax	226	272	(17)
EPS (in dollar)	5.06	6.10	(17)

The Differences Between 2023 and 2022

➤ Revenue


- Part of the factories have been rebuilt and production restored to enhance supply capacity.
- The price adjustment of some products and the impact of exchange rate have led to an increase in the selling price.

➤ Profit

- Gross profit ratio increased due to the increase in selling price and the change in the composition of products sold.
- The depreciation of the NT dollar against the US dollar has slowed down, significantly reducing the currency exchange gains.

EPS and Dividend in Recent 5 Years

Unit: NT in dollar



Overview of rebuild plants, facilities and equipments I

- Factory D has passed the TFDA GMP/GDP inspection in March 2023 and obtained the certificate.
- Factory C has passed the TFDA GMP/GDP inspection in August 2023 and obtained the certificate.
- Factory S has been inspected by TFDA in August 2023, and the certificate should be obtained recently.

Overview of rebuild plants, facilities and equipments II

- Factory T has been inspected and approved by the Animal and Plant Health Inspection Agency, Ministry of Agriculture in March 2023. The application for European EU R1-CEP and US FDA DMF is still under review.
- Factory F has been rebuilt and factory E is expected to be completed by the end of November. Factories E and F will apply for inspection together before the end of this year.
- The synthetic office building, heating-medium boiler room, and stability laboratory have all been completed.



Strategy in the Future Development & forward-looking

Strategy in the Future Development & forward-looking I

- To develop new products and expand their market share.
- Optimize the product manufacturing process, automate key steps to provide high-quality and affordable products :
 - Research and develop to improve the manufacturing process, plan the automation of key steps, and further optimize the quality of main products to make the products more competitive.
 - Factories C, D, E, F and S will all be completed before the end of November. After passing the TFDA inspection, production will be smoother and more efficient.
 - The market is changing rapidly, establishing a second supply chain. The main raw materials are developed and produced independently to maintain the sustainable production of important items.

Strategy in the Future Development & forward-looking II

- Carefully select and evaluate suitable new niche APIs for the future development:
 - In accordance with national needs, products are selected to be manufactured to avoid major international changes. In such a case of COVID-19, India has controlled the export of important drugs. This may cause domestic shortage of drugs, which can be avoided by taking appropriate measures.

- Expanding New Business Area:
 - APIs' key intermediates.
 - Develop our business in China market.
 - Special APIs' dosage forms.
 - Small quantities of specialty APIs.
 - Develop new drugs with other enterprises.



Thanks for your attention.

 生泰合成工業公司
SYN-TECH CHEM & PHARM CO., LTD

Stock Code : 1777